Standout Papers

Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of th... 1998 2026 2007 2016 2.4k
  1. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction (2001)
    John S. Macdonald, Stephen R. Smalley et al. New England Journal of Medicine
  2. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial (2014)
    H. Wilke, Kei Muro et al. The Lancet Oncology
  3. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group (2006)
    Eric Van Cutsem, Vladimir Moiseyenko et al. Journal of Clinical Oncology
  4. Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer (1998)
    David P. Kelsen, Robert J. Ginsberg et al. New England Journal of Medicine
  5. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression (2020)
    Guang Lei, Yilei Zhang et al. Cell Research
  6. Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection (2012)
    Stephen R. Smalley, Jacqueline Benedetti et al. Journal of Clinical Oncology
  7. Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal (2008)
    Jaffer A. Ajani JAMA
  8. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial (2010)
    Jaffer A. Ajani, W. Rodriguez et al. Journal of Clinical Oncology
  9. Gastric adenocarcinoma (2017)
    Jaffer A. Ajani, Jeeyun Lee et al. Nature Reviews Disease Primers
  10. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study (2017)
    Peter Thuss‐Patience, Manish A. Shah et al. The Lancet Oncology
  11. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study (2013)
    Atsushi Ohtsu, Jaffer A. Ajani et al. Journal of Clinical Oncology
  12. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin (2012)
    Leonard L. Gunderson, Kathryn Winter et al. Journal of Clinical Oncology
  13. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023)
    Kohei Shitara, Florian Lordick et al. The Lancet
  14. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database (2017)
    Haejin In, Ian Solsky et al. Annals of Surgical Oncology
  15. Drug resistance and Cancer stem cells (2021)
    Yuan Li, Zhenning Wang et al. Cell Communication and Signaling
  16. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study (2023)
    Eric Van Cutsem, Maria Di Bartolomeo et al. The Lancet Oncology
  17. Advances in diagnosis and management of cancer of the esophagus (2024)
    Nathaniel Deboever, Christopher M. Jones et al. BMJ

Immediate Impact

3 by Nobel laureates 4 from Science/Nature 172 standout
Sub-graph 1 of 17

Citing Papers

USP8-governed GPX4 homeostasis orchestrates ferroptosis and cancer immunotherapy
2024 Standout
Oesophageal cancer
2024 Standout
33 intermediate papers

Works of Jaffer A. Ajani being referenced

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 Standout
Clinical Staging of Patients with Early Esophageal Adenocarcinoma: Does FDG-PET/CT Have a Role?
2014
and 44 more

Author Peers

Author Last Decade Papers Cites
Jaffer A. Ajani 26242 20687 16398 923 44.0k
Yung‐Jue Bang 16587 7405 20426 602 36.1k
Heikki Joensuu 11879 6518 12609 570 34.2k
Yoon‐Koo Kang 13225 6704 11984 543 25.4k
Charles J. Yeo 17062 28533 41653 563 55.1k
George D. Demetri 23206 8720 10951 342 37.2k
Ian Judson 16160 4927 10674 402 27.4k
Samuel Singer 16327 4752 7981 326 28.2k
Michel Ducreux 10305 11207 25207 612 36.6k
Hyun Cheol Chung 13659 6961 14781 577 26.9k
John P. Neoptolemos 11698 21155 27654 507 39.3k

All Works

Loading papers...

Rankless by CCL
2026